Hanmi Pharmaceutical said that it has confirmed the global competitiveness of its obesity, diabetes and nonalcoholic steatohepatitis (NASH) treatment candidates, at the European Association for the Study of Diabetes held in Barcelona, Spain.
|Hanmi headquarters in Bangi-dong, eastern Seoul.|
The company presented nine posters session for its three bio-drug candidate materials, which it has been developing using the company’s patented Lapscovery technology.
The three new biopharmaceutical drugs announced at the conference are efpeglenatide, licensed out to Sanofi by Hanmi, “LAPSTriple Agonist,” nonalcoholic steatohepatitis (NASH) therapeutic drug candidate, and “LAPSGlucagon Analog,” obesity and rare disease treatment, Hanmi said in a news release.
LAPSTriple Agonist is a drug that simultaneously activates Glucagon-like peptide-1 (GLP-1), which helps increase insulin metabolism and insulin secretion and appetite suppression, and anti-inflammatory GIP receptors. This year the company presented three preclinical studies for the drug, which confirmed its excellent effects in animal models of NASH, dyslipidemia and neurodegenerative diseases.
Through the trial, Hanmi said it confirmed that LAPSTriple Agonist has excellent efficacy in improving fatty liver, liver inflammation and liver fibrosis in nonalcoholic steatohepatitis animal model, and also has superior blood cholesterol-lowering effects in the animal model of dyslipidemia, known as a significant cause of NASH.
The company also confirmed the potent anti-inflammatory action of LAPSTriple Agonist, identified during the study of NASH, could extend to various neurodegenerative diseases.
Hanmi also reaffirmed LAPSGlucagon Analog’s potential to become an obesity treatment after verifying excellent weight loss effect in an obese animal model.
Further mechanisms have also been ascertained, including LAPSGlucagon Analog’s ability to increase energy metabolism through dietary control and the browning of white fat, and identified a new mechanism for improving insulin resistance.
Based on these preclinical results, Hanmi Pharmaceutical said it is planning a clinical trial for obese patients.
Regarding efpeglenatide, Dr. Richard E. Pratley of the AdventHealth Clinical Implementation Institute presented a poster study on the exploratory small-group analysis data for the EXCEED 205 project that validated the drug’s efficacy in pre-diabetic patients.
The analysis showed that efpeglenatide improve HbA1c (glycosylated hemoglobin), FPG (fasting blood glucose), body weight, BMI (waist mass index), waist circumference, and total cholesterol levels compared to baseline.
“We will continue to demonstrate the R&D capabilities of Hanmi Pharm through the global conference and will speed up development for commercialization,” Hanmi CEO Kwon Se-chang said.